<?xml version="1.0" encoding="UTF-8"?>
<p>The outcome of viral therapy is influenced by viral load and viral genomic variations (especially viral genotypes and certain specific genomic variants). Various therapeutic agents showed variation in their efficacy during treatment; Table 
 <xref rid="Tab7" ref-type="table">28.7</xref> shows the susceptibility of various genotypes in viral disease hepatitis, and Table 
 <xref rid="Tab8" ref-type="table">28.8</xref> shows the therapeutic agents and their effect (drug efficacy) on various genotype/strain of hepatitis. In addition, major histocompatibility complex (MHC) class I and MHC class II polymorphisms (Thursz and Thomas 
 <xref ref-type="bibr" rid="CR168">1997</xref>), interleukin 10 polymorphism (Yee et al. 
 <xref ref-type="bibr" rid="CR186">2001</xref>), MxA promoter single-nucleotide polymorphisms (SNPs), and mannose-binding protein SNPs (Hijikata et al. 
 <xref ref-type="bibr" rid="CR61">2001</xref>) all have been supported to affect host immune and antiviral responses and thus are associated with disease progression and treatment response. 
</p>
